Friday, May 9th, 2014
14.00 - 14.15 Congress Opening: A. Falanga, F.R. Rickles, B. Brenner

14.15 - 16.30 Plenary Session 1: Epidemiology and risk factors for thrombosis in cancer
Chairs: MB Donati (Italy), B Brenner (Israel)

-PL-01 Advances in the diagnosis and management of pulmonary embolism
MV Huisman (Netherlands)

-PL-02 Predicting recurrent thrombosis in cancer: is it possible?
PA Kyrle (Austria)

-PL-03 Lymphoma and VTE: influence on mortality
RH White (USA)

-PL-04 New findings from the RIETE study
M Monreal (Spain)

Selected Abstracts
- OC-01 Non-O blood group, age at cancer diagnosis and asparaginase therapy are independent risk factors for venous thrombotic events in children with cancer

- OC-02 Role of arterial cardiovascular risk factors in the pathogenesis of Cancer related VTE
F. Dentali, M. Mantiero, J. Muzzolon, A. Pastore, W. Ageno, G. Pinotti (Italy)

17.00 - 19.15 Plenary Session 2: Hypercoagulability in cancer / Biomarkers for VTE
Chairs: N Key (USA), A D'Angelo (Italy)

- PL-05 Update on thrombotic risk stratification strategies
AA Khorana (USA)

-PL-06 Thrombogenic and fibrinolytic properties of microparticles
F Dignat-George (France)

-PL-07 Risk factors for VTE in cancer: Novel findings from the Vienna Cancer and Thrombosis Study (CATS)
C Ay (Austria)
Unconventional antithrombotics in cancer associated thrombosis
J Zwicker (USA)

Selected Abstracts
- OC-03 Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: further evidence of a prothrombotic role
C.M. Radu, M.T. Sartori, E. Campello, P. Ciccarino, A. Della Puppa, L. Spiezia, R. Scienza, P. Simioni (Italy)

- OC-04 Plasma markers of hemostatic activation, fibrinolysis, and angiogenesis in prostate cancer and advanced solid tumors: Relationship to stage and prognosis
G. Kaur, A. Ireland, P. Christos, M. Mikhail, J. Chapin, D. Nanus, S. Tagawa (USA)

19.30 Third Simon Karpatkin Memorial Lecture
Chair: A Falanga (Italy)
Introduction: FR Rickles (USA)
-Oncogenes and coagulation system - forces that modulate dormant and aggressive states in cancer
J Rak (Canada)

Saturday, May 10th, 2014
8.15 - 10.30 Plenary Session 3: Bleeding complications, microangiopathies and thrombocytopenias
Chairs: PM Sandset (Norway), C Velati (Italy)

- PL-09 Bleeding complications during anticoagulation in cancer
PW Kamphuisen (Netherlands)

- PL-10 Supportive management with blood products for cancer patients
AB Federici (Italy)

-PL-11 Thrombocytopenia in cancer
H Liebman (USA)

-PL-12 Cancer-related coagulopathies
M Levi (Netherlands)
Selected Abstracts

- **OC-05** Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia
  J. Thaler, I. Pabinger, C. Ay (Austria)

- **OC-06** Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism receiving anticoagulation

11.00 - 13.15 **Plenary Session 4: Hemostatic system and cancer progression**

*Chairs: H ten Cate (Netherlands), R Giavazzi (Italy)*

- **PL-13** Tumor-expressed coagulation proteases
  HH Versteeg (Netherlands)

- **PL-14** Role of the protein C receptor in cancer progression
  W Ruf (USA)

- **PL-15** Heparanase multiple effects in cancer
  Y Nadir (Israel)

- **PL-16** Glycosaminoglycans as anti-cancer targets
  M Belting (Sweden)

Selected Abstracts

- **OC-07** Multicentric hypercoagulation screening to predict risk assessment, early diagnosis and prognosis in cancer patients: the HYPERCAN study
  M. Marchetti, G. Masci, A. Santoro, F. De Braud, L. Celio, R. Labianca, M. Mandalà, B. Merelli, C. Tondini, G. Gasparini, R. Sarmiento, C. Tartari, C. Giaccherini, F. Piras, C. Verzeroli, L. Barcella, A. Vignoli, and A. Falanga on behalf of the HYPERCAN Investigators. (Italy)

- **OC-08** The Tissue Factor-thrombin pathway is upregulated in the stroma of pre-invasive breast cancer and further upregulated in aggressive invasive breast cancer phenotypes ............OC-08
14.15 - 16.30 **Plenary Session 5: Thrombosis in hematological disorders**  
*Chairs: C Francis (USA), T Barbui (Italy)*

- **PL-17** Microenvironment and multiple myeloma spread  
  A Vacca (Italy)

- **PL-18** Abnormal adhesion of red blood cells in polycythemia vera  
  W El Nemer (France)

- **PL-19** Thrombo-hemorrhagic deaths in acute promyelocytic leukemia  
  F Lo Coco (Italy)

- **PL-20** Role of complement in thrombosis  
  I Weitz (USA)

**Selected Abstracts**

- OC-09 Genetic predisposition and induced pro-inflammatory/pro-oxidative status may explain increased atherothrombotic risk during TKI treatment in chronic myeloid leukemia patients  
  L. Puccetti, L. Aprile, S. Galimberti, A. Gozzini, F. Scarpini, M. Defina, F. De Majo, C. Baratè, A. Sicuranza, V. Candi, B. Scappini, D. Raspadori, A. Gozzetti, A. Bosi, M. Petrini and M. Bocchia (Italy)

- OC-10 Spectrum of thrombin generation from normal controls to MGUS to multiple myeloma  
  B. Lipe, M. Roengvoraphoj, J. He, R. Reyes, A. Yacoub, T. Lin, D. Ornstein (USA)

17.00 - 19.15 **Plenary Session 6: Thromboprophylaxis in cancer**  
*Chairs: D Farge (France), R Labianca (Italy)*

- **PL-21** Guidelines for thromboprophylaxis in cancer patients: future challenges  
  GH Lyman (USA)

- **PL-22** Experience with the direct factor Xa inhibitors in cancer  
  MN Levine (Canada)

- **PL-23** New strategies for VTE prevention in cancer  
  G Agnelli (Italy)

- **PL-24** Heparins and cancer survival: where do we stand?  
  S Noble (UK)
Selected Abstracts
- **OC-11** A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients with active cancer hospitalized with an acute medical illness
  P. Moretto, G. Le Gal, M. Carrier (Canada)

- **OC-12** Multi-modality assessment of pharmacological thromboprophylaxis for lung cancer patients
  M. Alexander, S. Kirsa, M. MacManus, D. Ball, B. Solomon & K. Burbury (Australia)

**Sunday, May 11th, 2014**
8.15 - 10.30 **Plenary Session 7: Platelets and vascular endothelium**
*Chairs: Z Ruggeri (USA), M Cattaneo (Italy)*

- **PL-25** New models of platelet-based coagulation
  JW Heemskerk (Netherlands)

- **PL-26** Endothelial cell plasticity in inflammatory and pro-thrombotic diseases
  E Dejana (Italy)

- **PL-27** Mechanistic explanation for platelet contribution to cancer metastasis
  B Nieswandt (Germany)

- **PL-28** May aspirin have a role in cancer prevention and treatment?
  C Patrono (Italy)

Selected Abstracts
- **OC-13** Inhibition of platelet activation prevents the P-selectin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo
  S. Mezouar, R. Darbousset, F. Dignat-George, L. Panicot-Dubois, C.Dubois (France)

- **OC-14** Procoagulant phenotypes and F5, F10 and EPCR gene polymorphisms are associated with breast cancer susceptibility
11.00 - 13.15 **Plenary Session 8: Treatment of thrombosis in cancer**
*Chairs: PH Reitsma (Netherlands), P Prandoni (Italy)*

- **PL-29** Potential antidotes for reversal of new and old anticoagulants
  S Schulman (Canada)

- **PL-30** Overview of treatment of VTE in cancer patients
  AK Kakkar (UK)

- **PL-31** Perspectives for the use of new anticoagulants for thrombosis treatment
  AY Lee (Canada)

- **PL-32** Unsuspected pulmonary embolism in cancer
  M Di Nisio (Italy)

**Selected Abstracts**

- **OC-15** Prescription and long-term use of low-molecular-weight heparins (LMWH) in routine medical practice for the treatment of venous thromboembolism in patients with cancer: TROPIQUE a prospective, French national, multicenter, observational study
  D. Farge-Bancel, F. Cajfinger, on behalf of the TROPIQUE investigators (France)

- **OC-16** Outpatient management of cancer-related pulmonary embolism: Analysis of 562 consecutive patients from the EPIPHANY Study
  MA. Vicente, A. Carmona-Bayonas, C. Font, P.J. Fonseca, C. Beato, L. Faez, M. Biosca, O. Madridano, J. Plasencia, D.Calvo-Temprano, A. Dominguez, P. Arguis, Alejandro Puerta and R. Otero on behalf of the EPIPHANY Study Investigators. (Spain)

14.30 - 17.30 **Poster Sessions**